Rating for ATR
AptarGroup, Inc. (ATR)
Last aptargroup, inc. earnings: 4/30 05:04 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.aptar.com
Company Research
Source: Benzinga
Impact Snapshot
Event Time:
ATR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATR alerts
High impacting AptarGroup, Inc. news events
Weekly update
A roundup of the hottest topics
ATR
News
- AptarGroup, Inc. (NYSE: ATR) had its price target lowered by analysts at Raymond James from $190.00 to $175.00. They now have an "outperform" rating on the stock.MarketBeat
- Aptar Declares Quarterly DividendBusiness Wire
- Will AptarGroup (ATR) Beat Estimates Again in Its Next Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Aptar Announces Clinical Validation Study to Accelerate US FDA Approval of SmartTrack™ In-Vitro-in-Silico Platform for Pressurized Metered-Dose Inhalers [Yahoo! Finance]Yahoo! Finance
- Aptar Announces Clinical Validation Study to Accelerate US FDA Approval of SmartTrack™ In-Vitro-in-Silico Platform for Pressurized Metered-Dose InhalersBusiness Wire
ATR
Earnings
- 2/6/25 - Beat
ATR
Sec Filings
- 3/31/25 - Form DEFA14A
- 3/28/25 - Form ARS
- 3/28/25 - Form DEFA14A
- ATR's page on the SEC website